InsiderGlobe

CHRS

insider transactions

Coherus Oncology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 365d

Open-market Buys Sells All types

Buy Sell Non-market (grant · exercise · gift)

About CHRS insider trading

This page tracks insider transactions for Coherus Oncology, Inc. (CHRS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.